South Korea's GC Pharma (Green Cross) and Shincheonji Church are offering assistance to Latin American countries ravaged by the COVID-19 pandemic.

A recent breakthrough in GC Pharma’s COVID-19 research was achieved on December 6th 2020 when a COVID-19 patient recovered after receiving GC Pharma’s blood plasma therapy.

The therapy, GC5131, was developed by fractioning an antibody with the immunogenicity from the plasma of a recovered COVID-19 patient.

Many Latin American hospitals already use GC Pharma’s IVIG-SN treatment to save patients from various illnesses, and this breakthrough may also open doors for GC Pharma’s blood plasma therapy to be administered to Latin American COVID-19 patients.

In addition, Shincheonji Church provided a boost to GC Pharma’s COVID-19 treatment research through large-scale plasma donations. A total of 4000 Shincheonji members have successfully donated their blood plasma through three rounds that began in July. A member of Shincheonji Church said, “For the people around the world, [donating our blood] for a cure is the most valuable thing we can do after recovering from COVID-19.”

GC Pharma, a biotechnology pioneer in South Korea, is now preparing to take another major leap forward toward ensuring a healthier and happier future for all people worldwide. Challenge and innovation, care and compassion, transparency and integrity, and respect and dedication are the core principles that guide GC Pharma on its journey toward achieving its next goal.